Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3065 |
|
| Actual shortage: | 231 (8%) | |
| Anticipated shortage: | 16 (1%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2809 (92%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
30 (11%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2021-04-16 | 2021-05-01 | 137575 |
| APO-IBUPROFEN | 200MG | TABLET | Resolved | 2022-02-11 | 2022-05-14 | 154762 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2023-01-06 | 2023-02-09 | 180109 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2023-04-14 | 2023-04-21 | 189638 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2023-11-17 | 2023-12-01 | 210733 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2024-01-12 | 2024-03-29 | 215967 |
| APO-IBUPROFEN | 200MG | TABLET | Resolved | 2024-03-01 | 2024-03-29 | 221087 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2024-03-15 | 2024-04-05 | 222470 |
| APO-IBUPROFEN | 300MG | TABLET | Resolved | 2019-06-05 | 2021-01-11 | 85597 |
| APO-IBUPROFEN | 200MG | TABLET | Resolved | 2019-02-24 | 2020-04-01 | 76717 |
| APO-IBUPROFEN | 400MG | TABLET | Resolved | 2019-03-05 | 2021-01-11 | 77890 |
| APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2019-01-09 | 2021-01-04 | 71665 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2017-07-31 | 2017-09-06 | 17609 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2017-11-28 | 2018-04-18 | 31010 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2018-07-31 | 2018-11-15 | 56986 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2019-03-13 | 2019-03-29 | 78512 |
| APO-IMATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-02-11 | 132718 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2021-04-16 | 2021-05-17 | 137578 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2021-06-25 | 2021-07-12 | 141532 |
| APO-IMATINIB | 400MG | TABLET | Resolved | 2022-02-18 | 2022-03-21 | 155314 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
| APO-CARBAMAZEPINE | Discontinued | 2020-02-19 | 2020-02-19 | 106679 |